(a) NO levels in SLAM cells obtained from the bone marrow
and peripheral blood. NOlow gating represents baseline reactivity;
n = 3. (b) FACS analysis of eNOS Ser1177
phosphorylation in BM LSK cells 30 minutes following thrombin injection;
n = 4. (c) Kinetics of eNOS phosphorylation on
Ser1177 and Thr495 in bone marrow LSK cells following in vitro
thrombin stimulation; n = 4. (d) Circulating LSK
cells and bone marrow EPCR+ LSK cells following thrombin injection in
mice pretreated with or without l-NAME; n = 6,
P values, one-way ANOVA with Tukey’s post-test.
(e) Circulating LSK cells and bone marrow EPCR+ LSK
cells in wild-type or Nos3−/− bone
marrow chimeric mice following thrombin injection; n = 4.
(f) Circulating LSK cells and bone marrow EPCR+ LSK
cells 60 minutes after SNAP injection; n = 4. (g)
Cdc42 (purple) distribution on bone marrow EPCR+ (yellow) LSK cells
10 minutes following in vivo thrombin treatment. Scale bar, 7
µm. (h) FACS analysis of Cdc42-GTP following in
vitro thrombin treatment for 15 minutes of bone marrow SK SLAM
cells that had been pretreated with or without l-NAME for 2 hours;
n = 4, P values, one-way ANOVA with
Tukey’s post-test. (i) Cdc42-GTP in bone marrow SK SLAM
cells (left) and LDV-FITC binding to bone marrow EPCR+ SK SLAM cells
(right) following in vitro treatment with SNAP for 15 minutes;
n = 4.